| Literature DB >> 27242408 |
Abstract
Entities:
Keywords: Alzheimer disease; LTP; autism; endocannabinoid; fragile X syndrome; neural circuits; synaptic plasticity; β-neurexins
Year: 2016 PMID: 27242408 PMCID: PMC4873487 DOI: 10.3389/fnins.2016.00203
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1Transsynaptic regulation of endocannabinoid signaling by β-neurexins and its implications in synaptic plasticity and diseases. (A) Regulation of excitatory synaptic strength by β-neurexins via endocannabinoid system. Anderson et al. demonstrated that presynaptic β-neurexins regulate endocannabinoid signaling by controlling postsynaptic endocannabinoid 2-AG synthesis. When β –neurexins are removed, 2-AG synthesis is disinhibited, presynaptic CB1Rs are activated, and synaptic strength is decreased (Anderson et al., 2015). In addition, the AC-PKA dependent LTP in burst-firing neurons is blocked, which may account for the impaired contextual memory in hippocampal CA1 β-neurexin knockout mice. β-neurexins act as a brake on endocannabinoid signaling possibly via transsynaptic interaction with postsynaptic neuroligin isoforms that exclusively bind to β-neurexins, but not a-neurexins (Anderson et al., 2015). β-neurexins might downregulate tonic endocannabinoid signaling through mGluR1/5 or M1/M3 receptors since activation of those GPCRs is known to trigger 2-AG production via PLC pathway (Varma et al., 2001; Chevaleyre et al., 2006; Heifets and Castillo, 2009; Kano et al., 2009; Castillo et al., 2012; Rinaldo and Hansel, 2013; Martin et al., 2015). This regulation might also involve VGCCs, NMDARs, or AMPARs as Ca2+ influx through these channels could facilitate PLC-DAGL mediated 2-AG production (Ohno-Shosaku et al., 2005; Castillo et al., 2012). The exact postsynaptic partners of β-neurexins in this process await to be identified. (B) The regulation of endocannabinoid signaling by β-neurexins supports neurexins/neuroligins-endocannabinoid signaling as a common pathomechanism in cognitive disorders (Krueger and Brose, 2013; Anderson et al., 2015). Abnormalities in this signaling pathway could disrupt synapses and neural circuits, and contribute to neurological and psychiatric diseases (Chubykin et al., 2005; Tabuchi et al., 2007; Katona and Freund, 2008; Sudhof, 2008; Gogolla et al., 2009; Bot et al., 2011; Etherton et al., 2011; Foldy et al., 2013; Singh and Eroglu, 2013; Rothwell et al., 2014; Sindi et al., 2014; Aoto et al., 2015; Bedse et al., 2015; Born et al., 2015; Di Marzo et al., 2015; Parsons and Hurd, 2015; Wang and Doering, 2015; Wang et al., 2015; Bemben et al., 2015b; Chanda et al., 2016). Abbreviations: 2-AG, 2-arachidonoyl-sn-glycerol; AC, adenylyl cyclase; AMPAR, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CB1R, cannabinoid receptor 1; DAG, diacylglycerol; DAGL, diacylglycerol lipase; LTP, long-term potentiation; M1/3R, muscarinic acetylcholine receptor 1/3; mGluR, metabotropic glutamate receptor; NMDAR, N-methyl-D-aspartate receptor; PIP2, phosphatidylinositol 4, 5-bisphosphate; PKA, protein kinase A; PLC, phospholipase C; VGCC, voltage-gated Ca2+ channels.